A comparative study of Ocusert Pilo 40, intensive pilocarpine and low-dose pilocarpine in the initial treatment of primary acute angle-closure glaucoma.
Acetazolamide and pilocarpine have a central role in the initial management of primary acute angle closure glaucoma (PACG), but there is no consensus concerning their mode of delivery, as borne out by a recent survey of senior UK ophthalmologists reported below. Ocusert Pilo 40 was developed to remain in situ releasing pilocarpine for up to one week. In view of its potential advantages, a trial of Ocusert Pilo 40's efficacy in PACG was conducted. In two separate controlled studies, eyes diagnosed with PACG were randomised to receive Ocusert Pilo 40, and either an intensive pilocarpine regimen or a low-dose pilocarpine treatment. All patients also received Diamox 500 mg i.v. Two hours after starting topical treatment, the study was terminated and ocular and systemic response to treatment and the eventual outcome were assessed. In both studies, intravenous Diamox caused a fall of intraocular pressure (IOP) within 30 min. Over the treatment period, a comparable reduction in IOP was seen in the Ocusert-treated, the intensive-pilocarpine-treated, and the low-dose-pilocarpine-treated groups. No damage to the corneas were observed.
Edwards
R S
RS
Birmingham and Midland Eye Hospital, UK.
D000086:Acetazolamide / Q000008:administration & dosage; D000208:Acute Disease; D003692:Delayed-Action Preparations; D015812:Glaucoma, Angle-Closure / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D010862:Pilocarpine / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D016896:Treatment Outcome
D003692:Delayed-Action Preparations; D010862:Pilocarpine; D000086:Acetazolamide